NO314595B1 - Fremgangsmåte for fremstilling av et kim¶rt terapeutisk aktivt humanisert antistoff eller et terapeutisk aktivt fragment derav, DNA-sekvenssom koder for antistoffet, samt plasmid og stabil vertscellelinje som omfatterDNA-sekvensen - Google Patents

Fremgangsmåte for fremstilling av et kim¶rt terapeutisk aktivt humanisert antistoff eller et terapeutisk aktivt fragment derav, DNA-sekvenssom koder for antistoffet, samt plasmid og stabil vertscellelinje som omfatterDNA-sekvensen Download PDF

Info

Publication number
NO314595B1
NO314595B1 NO19930825A NO930825A NO314595B1 NO 314595 B1 NO314595 B1 NO 314595B1 NO 19930825 A NO19930825 A NO 19930825A NO 930825 A NO930825 A NO 930825A NO 314595 B1 NO314595 B1 NO 314595B1
Authority
NO
Norway
Prior art keywords
antibody
dna sequence
genetic engineering
fragment
human
Prior art date
Application number
NO19930825A
Other languages
English (en)
Norwegian (no)
Other versions
NO930825L (no
NO930825D0 (no
Inventor
Martine Elisa Verhoeyen
Original Assignee
Imp Cancer Res Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp Cancer Res Tech filed Critical Imp Cancer Res Tech
Publication of NO930825D0 publication Critical patent/NO930825D0/no
Publication of NO930825L publication Critical patent/NO930825L/no
Publication of NO314595B1 publication Critical patent/NO314595B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nonmetallic Welding Materials (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
NO19930825A 1990-09-07 1993-03-05 Fremgangsmåte for fremstilling av et kim¶rt terapeutisk aktivt humanisert antistoff eller et terapeutisk aktivt fragment derav, DNA-sekvenssom koder for antistoffet, samt plasmid og stabil vertscellelinje som omfatterDNA-sekvensen NO314595B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909019553A GB9019553D0 (en) 1990-09-07 1990-09-07 Specific binding agents
PCT/GB1991/001511 WO1992004380A1 (en) 1990-09-07 1991-09-05 Specific binding agents

Publications (3)

Publication Number Publication Date
NO930825D0 NO930825D0 (no) 1993-03-05
NO930825L NO930825L (no) 1993-05-05
NO314595B1 true NO314595B1 (no) 2003-04-14

Family

ID=10681827

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19930825A NO314595B1 (no) 1990-09-07 1993-03-05 Fremgangsmåte for fremstilling av et kim¶rt terapeutisk aktivt humanisert antistoff eller et terapeutisk aktivt fragment derav, DNA-sekvenssom koder for antistoffet, samt plasmid og stabil vertscellelinje som omfatterDNA-sekvensen
NO20014822A NO315239B1 (no) 1990-09-07 2001-10-04 Kim¶rt humanisert antistoff eller fragment derav, samt anvendelse av samme

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20014822A NO315239B1 (no) 1990-09-07 2001-10-04 Kim¶rt humanisert antistoff eller fragment derav, samt anvendelse av samme

Country Status (18)

Country Link
US (2) US6204366B1 (da)
EP (1) EP0483961B1 (da)
JP (2) JP3514456B2 (da)
KR (1) KR930702526A (da)
AT (1) ATE233279T1 (da)
AU (1) AU653167B2 (da)
BG (1) BG60716B1 (da)
CA (1) CA2090961C (da)
DE (1) DE69133200T2 (da)
DK (1) DK0483961T3 (da)
ES (1) ES2193129T3 (da)
FI (2) FI113873B (da)
GB (1) GB9019553D0 (da)
HU (2) HU9300609D0 (da)
NO (2) NO314595B1 (da)
RO (1) RO113432B1 (da)
UA (1) UA46691C2 (da)
WO (1) WO1992004380A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP0571613B1 (en) * 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
WO1994011508A2 (en) * 1992-11-13 1994-05-26 Cancer Research Fund Of Contra Costa Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
US5792852A (en) * 1992-11-16 1998-08-11 Cancer Research Fund Of Contra Costa Polynucleotides encoding modified antibodies with human milk fat globule specificity
US6281335B1 (en) * 1993-10-08 2001-08-28 Coulter Corporation Hybridoma and anti-KC-4 humanized monoclonal antibody
AU6396494A (en) * 1992-11-16 1994-06-08 Cancer Research Fund Of Contra Costa Peptides and anti-sense peptides with broad neoplastic specificity
US5804187A (en) 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
JPH07203974A (ja) * 1994-01-13 1995-08-08 Tosoh Corp 癌特異的ムチンを認識する抗体の遺伝子断片等
EP0781847A1 (en) * 1995-11-06 1997-07-02 MERCK PATENT GmbH Humanized monoclonal antibody
IL136114A0 (en) * 1997-11-14 2001-05-20 Euro Celtique Sa Immunoglobulin molecules having a synthetic variable region and modified specificity
GB2360771A (en) * 2000-03-28 2001-10-03 Antisoma Res Ltd Compounds for targeting
WO2001074905A1 (en) * 2000-04-03 2001-10-11 Antisoma Research Limited Compounds for targeting
AU2002307064A1 (en) * 2001-04-02 2002-10-15 Purdue Pharma L.P. Immunoglobulin construct containing anti-mucin variable domain sequences for eliciting an anti-idiotype anti-tumor response
GB0200657D0 (en) * 2002-01-12 2002-02-27 Antisoma Plc Cancer treatment
CA2488441C (en) * 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
AU2003256566A1 (en) * 2002-07-16 2004-02-02 Stuart Bussell Methods to construct multimeric dna and polymeric protein sequences as direct fusions or with linkers
AU2004261980A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody CDR polypeptide sequences with restricted diversity
GB0519398D0 (en) * 2005-09-23 2005-11-02 Antisoma Plc Biological materials and uses thereof
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
EP1973951A2 (en) * 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
KR101920250B1 (ko) 2010-10-13 2018-11-20 얀센 바이오테크 인코포레이티드 인간 온코스타틴 m 항체 및 이용 방법
US20140079722A1 (en) * 2011-03-09 2014-03-20 Centrose, Llc Extracellular targeted drug conjugates
RU2493165C1 (ru) * 2012-02-28 2013-09-20 Общество с ограниченной ответственностью "Технофарма" Наноантитело, специфически связывающее белок muc1, способ детекции белка muc1 с помощью наноантител
EP3363462A1 (en) 2012-04-30 2018-08-22 Biothera, Inc. Compositions and methods for beta-glucan immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
CA1339204C (en) * 1987-01-07 1997-08-05 Joyce Taylor-Papadimitriou Mucin core polypeptide, antibodies and probes
ATE243754T1 (de) * 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
AU3049189A (en) * 1988-02-08 1989-08-25 John Muir Cancer & Aging Institute Monoclonal antibody specific to a novel mucin-like glycoprotein surface antigen on human carcinoma cells
EP0442926A1 (en) * 1988-11-10 1991-08-28 Imperial Cancer Research Technology Limited Polypeptides
CA2003211A1 (en) * 1988-11-17 1990-05-17 Pei-Xiang Xing Monoclonal antibodies
US5075219A (en) * 1989-04-05 1991-12-24 John Muir Cancer & Aging Institute Monoclonal antibody which recognizes a specific glycoprotein of a human milk-fat globule membrane mucin antigen and said mucin antigen
ES2075169T3 (es) * 1989-11-17 1995-10-01 Unilever Nv Agentes de union especifica.

Also Published As

Publication number Publication date
ES2193129T3 (es) 2003-11-01
NO930825L (no) 1993-05-05
NO315239B1 (no) 2003-08-04
ATE233279T1 (de) 2003-03-15
HU9300609D0 (en) 1993-05-28
JPH06500468A (ja) 1994-01-20
WO1992004380A1 (en) 1992-03-19
HUT67796A (en) 1995-04-28
US6204366B1 (en) 2001-03-20
NO20014822D0 (no) 2001-10-04
NO930825D0 (no) 1993-03-05
CA2090961C (en) 2004-01-20
GB9019553D0 (en) 1990-10-24
DE69133200T2 (de) 2003-11-20
AU8495391A (en) 1992-03-30
FI930984A0 (fi) 1993-03-05
AU653167B2 (en) 1994-09-22
FI930984L (fi) 1993-03-05
DK0483961T3 (da) 2003-06-23
BG97607A (bg) 1994-03-31
US20020086978A1 (en) 2002-07-04
FI114611B (fi) 2004-11-30
JP3514456B2 (ja) 2004-03-31
EP0483961A1 (en) 1992-05-06
KR930702526A (ko) 1993-09-09
UA46691C2 (uk) 2002-06-17
DE69133200D1 (de) 2003-04-03
FI113873B (fi) 2004-06-30
RO113432B1 (ro) 1998-07-30
CA2090961A1 (en) 1992-03-08
EP0483961B1 (en) 2003-02-26
BG60716B1 (en) 1996-01-31
NO20014822L (no) 1993-05-05
JP2003061689A (ja) 2003-03-04

Similar Documents

Publication Publication Date Title
NO314595B1 (no) Fremgangsmåte for fremstilling av et kim¶rt terapeutisk aktivt humanisert antistoff eller et terapeutisk aktivt fragment derav, DNA-sekvenssom koder for antistoffet, samt plasmid og stabil vertscellelinje som omfatterDNA-sekvensen
US5891996A (en) Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use
RU2112037C1 (ru) Гибридное моноклональное антитело, взаимодействующее с cd4-антигеном т-хелперных клеток человека, и способ его получения
EP0491031B1 (en) Cdr grafted anti-cea antibodies and their production
JPH08504080A (ja) 変性された抗体、それに関連する生成物及び方法
JPH02501191A (ja) 組換え抗体及び方法
GB2276169A (en) Antibodies specific for carcinoembryonic antigen
KR970007782B1 (ko) 특이적 결합제
Sompuram et al. Analysis of antigen binding and idiotypic expression by antibodies with polyglycine-replaced complementarity-determining regions
RU2102479C1 (ru) Химерное моноклональное антитело, взаимодействующее с человеческой плацентарной щелочной фосфатазой, вариабельная область тяжелой гамма-цепи химерного моноклонального антитела, вариабельная область легкой k-цепи химерного моноклонального антитела, фрагмент кднк, кодирующий вариабельную область тяжелой гамма-цепи химерного моноклонального антитела и фрагмент кднк, кодирующий вариабельную область легкой k-цепи химерного моноклонального антитела
JPH06189768A (ja) Ｂ型肝炎ウイルスのｐｒｅ−Ｓ２抗原に対するキメラ抗体およびその産生細胞株
HK1180347A (en) Anti-neuropilin antibodies and methods of use

Legal Events

Date Code Title Description
MK1K Patent expired